ENTRY       D10985                      Drug
NAME        Sacituzumab govitecan (USAN/INN);
            Sacituzumab govitecan (genetical recombination) (JAN);
            Sacituzumab govitecan-hziy;
            Trodelvy (TN)
PRODUCT     TRODELVY (Gilead Sciences)
REMARK      ATC code: L01FX17
            Product: D10985<US>
EFFICACY    Antineoplastic, Topoisomerase I inhibitor
  DISEASE   Breast cancer (triple negative) [DS:H00031]
  TYPE      Antibody-drug conjugate
TARGET      TOP1 [HSA:7150] [KO:K03163]
            TACSTD2 (TROP2) [HSA:4070] [KO:K17288]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
                L01FX Other monoclonal antibodies and antibody drug conjugates
                 L01FX17 Sacituzumab govitecan
                  D10985  Sacituzumab govitecan (USAN/INN) &lt;US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Monoclonal Antibody/Antibody-Drug Conjugate
               Sacituzumab Govitecan
                D10985  Sacituzumab govitecan (USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               Other
                TACSTD2 (TROP2)
                 D10985  Sacituzumab govitecan (USAN/INN) &lt;US&gt;
             Enzymes
              Isomerases (EC5)
               DNA topoisomerase
                TOP1
                 D10985  Sacituzumab govitecan (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10985
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10985
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10985
            Pharmacogenomic biomarkers [br08341.html]
             Somatic variations in targeted cancer therapies
              D10985
             Polymorphisms and mutations affecting drug response
              D10985
DBLINKS     CAS: 1491917-83-9
            PubChem: 350078336
///
